GRI Bio (GRI) Cash from Financing Activities (2020 - 2026)
GRI Bio (GRI) posted quarterly Cash from Financing Activities of $6.5 million for Q1 2026, up 59227.27% year-over-year from N/an in Q1 2025, and down 9.01% quarter-over-quarter from $7.1 million in Q4 2025.
GRI Bio (GRI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
GRI Bio's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $6.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 59227.27% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $19.9 million (up 171.41% YoY), while the FY2025 annual figure was $13.4 million, up 13.18% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $6.5 million, down from $7.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $7.1 million in Q4 2025, with the low at -$23000.0 in Q1 2022.
- The 5-year median for Cash from Financing Activities is $1.8 million (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 100.25% in 2025, then surged 59227.27% in 2026.
- GRI Bio's Cash from Financing Activities stood at $752000.0 in 2022, then soared by 415.96% to $3.9 million in 2023, then tumbled by 41.21% to $2.3 million in 2024, then surged by 213.37% to $7.1 million in 2025, then fell by 9.01% to $6.5 million in 2026.
- Business Quant data shows GRI's Cash from Financing Activities at $6.5 million in Q1 2026, $7.1 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - | 1.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.50 Mn |
| Mar 31, 2026 | 6.50 Mn |
| Dec 31, 2025 | 7.15 Mn |
| Dec 31, 2025 | 7.15 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 5.01 Mn |
| Jun 30, 2025 | 5.01 Mn |
| Mar 31, 2025 | -11,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | 2.28 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 661,000.00 |
| Sep 30, 2024 | 661,000.00 |
| Jun 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | 4.40 Mn |
| Mar 31, 2024 | 4.49 Mn |
| Mar 31, 2024 | 4.49 Mn |
| Dec 31, 2023 | 3.88 Mn |
| Dec 31, 2023 | 3.88 Mn |